Redefining Immune Activation: A Strategy for Safer, Scalable Bispecific Cancer Therapeutics

In oncology, bispecific antibodies have long promised a revolution—uniting the precision of targeted therapy with the immune system’s killing power. Yet for solid tumors, a stubborn question persists: how do you activate T-cells precisely at the tumor site without triggering systemic toxicity?

AP Biosciences (APBio), a clinical-stage biotech founded in Taiwan in 2013, believes it has an answer. The company has developed a suite of proprietary technologies that aim to deliver safer, smarter immune activation for cancer patients—beginning with their two core platforms: OmniMab and T-Cube.

At BIO 2025 in Boston, Spike Lo, Vice President of Business Development, shared how these technologies are shaping AP’s pipeline and setting it apart in a crowded immuno-oncology landscape.

Engineering Smarter Antibodies Starts with the Right Tools

AP Biosciences built its technology foundation early. Instead of rushing to develop a lead asset, the team prioritized a modular discovery platform. That platform, called OmniMab, is a phage-display library designed to identify a wide range of antibody light chains quickly.

“OmniMab lets us screen diverse binders efficiently,” Lo explained. “It gives us the flexibility to explore complex targets and combinations.” This approach reflects a growing trend in biotech: build adaptable tools first, then build a pipeline. Companies that invest in internal discovery systems often iterate faster and adjust more easily as scientific priorities shift.

OmniMab supports exactly that. Its design allows researchers to switch targets or formats without restarting from scratch—something increasingly valuable in an industry defined by speed and precision.

Targeting Tumors with Surgical Precision

While OmniMab casts a wide net, T-Cube, APBio’s second core platform, offers surgical focus. Designed for bispecific antibody development, T-Cube is built around CD137 (4-1BB)—a well-known T-cell costimulatory molecule. But unlike traditional CD137 agonists, which have failed in trials due to systemic toxicity, T-Cube takes a more controlled approach.

“Our bispecific format activates T-cells only in the presence of the target antigen,” Lo said. “That means activation happens inside the tumor, not systemically.” This kind of conditional activation matters. CD137 is a powerful immune switch, but without spatial control, it can do more harm than good. APBio’s design aims to avoid liver toxicity and cytokine release syndrome—two major safety issues that plagued earlier candidates.

The early data is encouraging. In preclinical studies presented at the AACR Annual Meeting, APBio’s T-Cube-based antibody (AP402) triggered potent tumor regression and strong T-cell activation, without affecting healthy tissues. It’s a promising sign that controlled engagement can deliver on both efficacy and safety.

Focused Programs, Global Intent: From Platform to Pipeline

APBio’s platforms have now produced two clinical candidates. AP505, a PD-L1/VEGF-targeting bispecific antibody, is attracting partnering interest. Meanwhile, AP402 targets p95HER2, a truncated form of HER2 found in resistant breast cancers.

Choosing p95HER2 reflects a smart strategy: go narrow before going broad. This biomarker, present in about 30–40% of HER2-positive tumors, represents a high-need, less crowded opportunity. It allows APBio to validate its technology in a defined patient population before expanding to other indications—an approach that serves both scientific and strategic goals.

In oncology, starting with a tightly defined patient group increases the likelihood of observing a clear therapeutic effect. It streamlines trial design, aligns with regulatory incentives for precision medicine, and lowers early development risk. For potential partners, it also provides a sharper proof-of-concept and de-risks the broader application of the platform.

This focus makes partnering conversations more concrete. At BIO 2025, Lo noted that AP505 is generating strong interest, especially from companies looking to co-develop assets for global markets. “We’re talking with strategic partners now,” he said. “The hope is to take this program from Taiwan to broader international development.”

To that end, APBio has already dosed its first patient in a Phase 1/2 trial in Australia, marking a major step toward international clinical presence.

Designing for Scalability from the Start

Beyond discovery and targeting, APBio has also considered manufacturing—a step that many early-stage biotechs delay until it becomes a problem. With its T-Cube platform, the company designed its antibodies for symmetry, structural simplicity, and processability, avoiding the pitfalls of overly complex bispecific formats.

This kind of foresight matters. In biopharmaceutical development, manufacturability is often the hidden gatekeeper. A therapy may be scientifically sound and clinically promising, yet stumble during scale-up due to difficulties in purification, stability, or reproducibility. Many first-generation bispecifics, for example, struggled with asymmetric structures that complicated production, increased costs, and slowed time to clinic.

APBio’s design choices address these risks upfront. By building bispecifics that are structurally balanced and compatible with standard expression systems, the company reduces variability and simplifies quality control. This translates into fewer headaches in the GMP manufacturing phase and a faster, smoother transition into clinical trials and eventual commercial scale.

For other biotechs, the lesson is clear: start with the end in mind. Therapies must not only work—they must scale efficiently under regulatory scrutiny. Teams should involve CMC (Chemistry, Manufacturing, and Controls) expertise early in the design process, not just during IND submission. Considering manufacturability from day one can save years and millions of dollars later in development.

APBio’s strategy shows that scientific innovation and operational pragmatism can—and should—go hand in hand. The company isn’t just optimizing for scientific outcomes; it’s optimizing for the real-world path to market.

A Blueprint for the Next Generation of Biotech

AP Biosciences is not just advancing drug candidates—it’s modeling how to build an early-stage biotech for long-term success. Its decisions reveal lessons for others in the field.

By building internal platforms before launching a full pipeline, the company created flexibility and speed. Then, by focusing on conditional activation, it tackled the safety challenges that set back competitors. And finally, by selecting niche, high-need targets, it positioned itself for differentiation. Ultimately, by considering scalability and global reach early, it prepared for real-world development demands.

Lo didn’t frame these as grand strategies—but the result is clear: APBio has built a startup that moves deliberately and defensibly through a competitive landscape. “We’re optimistic about what’s ahead,” he said. “By BIO 2026, we hope to share strong updates.”

As the field of bispecific antibodies matures, the questions are changing. It’s no longer just about whether you can engage immune cells—it’s about where, when, and how you activate them. AP Biosciences is betting that precision isn’t just molecular—it’s spatial, temporal, and systemic. And in a space where small choices early on can dictate success years later, their approach may offer a roadmap for others to follow.

“Our approach is about control—activating T-cells exactly where they’re needed, not everywhere,” said Spike Lo (right), Vice President of Business Development at AP Biosciences, as he spoke with GeneOnline (left) about the company’s bispecific antibody strategy and global ambitions during the 2025 BIO International Convention in Boston. Image: GeneOnline.

Related posts:

Fast-Tracking Biotech Innovation: How ITRI Is Overcoming Bottlenecks and Fueling Taiwan’s Global Startup Boom From Labs to Markets: BIO 2025 Sets the Global Biotech Playbook Rare Disease Diagnosis in Minutes: 3billion’s AI-Driven Genomic Platform Explained From Fabs to Labs: TSMC, Mayo Clinic, and the Next Wave of Bio-Digital Innovation in Phoenix

Author

Bernice Lottering